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Summary Thirty-one patients were entered into a pilot study combining oral quinidine with epirubicin
100 mg m 2 as first line chemotherapy in advanced breast cancer. Three patients were treated with quinidine
I g b.d., and developed symptoms of toxicity. Of eight subsequent patients treated with quinidine 500 mg b.d.,
two experienced tiredness and nausea and one severe oral toxicity with epirubicin. The remaining 20 patients
received quinidine 250 mg b.d.; one developed cinchonism and one malaise, the remainder showing no excess
toxicity compared with epirubicin alone. The median nadir WBC was similar with or without quinidine (2.3 vs
1.6 x 10'1-') as was median nadir platelet count (175 vs 157 x 1091-'). There was no evidence of significant
cardiac toxicity. The median plasma quinidine level achieved was 5.6 lmoll-I (range 2.1-22.1), which is
within the range of concentrations which is effective in vitro at reversing experimental anthracycline resistance.
A randomised controlled study is proposed to assess the impact of this potential modulation on the efficacy of
epirubicin in advanced breast cancer.
Adriamycin is the most effective single agent in the treatment
of advanced breast cancer (Carter, 1976). Tumour cell resis-
tance to adriamycin and other anthracyclines limits the
effectiveness of these drugs in breast cancer.
One mechanism of resistance demonstrated in vitro
depends on increased expression of the multidrug resistant
(MDR) gene which leads to increased production of a
specific membrane glycoprotein, P-glycoprotein (Kaye,
1988 ). P-glycoprotein confers resistance by functioning as an
energy-dependent efflux pump at the cell membrane, reducing
intracellular drug concentration and hence reducing cytotox-
icity. It has been shown experimentally that non-cytotoxic
drugs such as verapamil and quinidine can reverse this pro-
cess by binding to P-glycoprotein (Tsuruo et al., 1984; Yusa
& Tsuruo, 1989). In the MDR resistant breast cancer cell line
MCF-7, quinidine has been found to be an effective
modulator of resistance, increasing by 8-fold the sensitivity of
this line to adriamycin (Stallard & Kaye, 1989).
Although expressed in some cell lines and certain normal
tissues it is uncertain to what extent increased expression of
the MDR gene is relevant in patients with drug resistant
breast cancer. Recent work in our department, however, has
shown that of tumours from 49 patients with untreated
breast cancer, approximately 50% have detectable MDR-
mRNA present, with 10-15% of samples having very high
levels (Brown et al., 1989), equivalent to that seen in cell
lines. It would therefore seem possible that modulators such
as quinidine might improve the response rate to anthracyc-
lines in some patients with breast cancer.
A pilot study was therefore undertaken to determine the
feasibility of the use of quinidine combined with epirubicin,
in particular to assess the toxicity of this combination com-
pared with epirubicin alone, and to establish whether the
levels of quinidine which can be achieved in patients are close
to those active in vitro. Previous studies with modulators
such as verapamil have concluded that failure to achieve an
effective plasma concentration is a major limitation to this
approach, unless appropriate modulators are chosen.
Patients and methods
Thirty-one patients with locally advanced or metastatic
breast cancer were included. All patients were of WHO
performance 2 or less and the median age at entry was 56
years (range 35-69). Patients with elevated bilirubin or
evidence of active cardiac disease were excluded.
Treatment
Epirubicin was given at a dose of 100 mg m-2 at 3-weekly
intervals for a maximum of eight cycles. Epirubicin was given
alone for the first course followed on the same day by an
oral test dose of 250mg of quinidine to exclude hypersen-
sitivity. For subsequent courses patients received oral
quinidine durules for 4 days before epirubicin and 1 day
following. A twice daily regime of durules was chosen so that
steady state levels would be achieved.
Initially a dose of quinidine 1 g b.d. was chosen as this was
known to be tolerated by patients with cardiac disease. This
dose produced symptoms of toxicity in three patients and
there was also some evidence of toxicity in some patients
treated with 500 mg b.d. The majority of those entering the
study (20) have been treated with quinidine 250 mg b.d.
Toxicity monitoring
Toxicity with each course was assessed according to WHO
gradings. Nadir full blood counts were performed on most
patients on day 10. Particular attention was paid to cardiac
toxicity. A 12-lead electrocardiogram was performed with
each chemotherapy treatment and 24 h ambulatory monitor-
ing was performed with the first and second course. Echocar-
diography was carried out before the first and where possible
after the last course to assess left ventricular ejection fraction.
By having their first course of treatment with epirubicin
alone patients were able to act as their own controls for
comparison with toxicity from subsequent courses with
quinidine.
Quinidine levels
At the time of epirubicin administration blood was taken for
estimation of plasma quinidine concentrations using an
ELISA assay system.
Results
Toxicity
Quinidine I g b.d. Three patients were entered at this dose.
Two developed symptoms of cinchonism (dizziness, ringing
in the ears, visual disturbance) and one developed nausea
attributed to the quinidine.
Quinidine 500 mg b.d. Eight patients were in this group.
Two were removed from study because of toxicity, one oral
toxicity and the other due to nausea and lethargy. One was
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reduced to a dose of quinidine 250 mg b.d. after the second
course because of anorexia and continued to the full eight
courses without problems. Two patients developed progres-
sive disease, and the remaining three completed the planned
eight cycles although one of these was at a reduced dose of
epirubicin because of myelosuppression with the first cycle.
Quinidine 250 mg b.d. There were 20 patients entered at this
quinidine dose and there have been 77 patient cycles of
epirubicin with quinidine 250 mg b.d. Two patients developed
some toxicity attributed to quinidine; one developed symp-
toms ofcinchonism and one developed less specific symptoms
of dizziness. One patient was taken off the study because she
had been crushing the quinidine durules and another because
of oral toxicity after the first course with epirubicin alone.
One patient completed only seven courses because of nausea
and vomiting while three others stopped chemotherapy
before completing eight courses despite partial responses, one
because of myelosuppression, one because of an epirubicin
related skin reaction distant from the injection site, and one
because she declined the final course. Six completed all plan-
ned therapy while seven failed to respond and discontinued
epirubicin. (Table I).
Haematological toxicity The median nadir WBC with the
first course of epirubicin, without quinidine, was 2.3 x I0 1-'
(range 1.1-4.5) while that for courses 2-4, with quinidine
250mg b.d., was 1.5 x 10 1-' (range 1.0-5.9). The equiva-
lent values for platelets with and without quinidine were
175 x 109 1` (range 85-565) and 158 x 109 1-' (range
37-565). The median nadirs for subsequent courses with
quinidine were similar and did not show evidence of
cumulative toxicity (Table II).
There was no evidence of increased nausea and vomiting
or mucositis compared with epirubicin 100 mg m-2 alone.
Hair loss occurred in all patients.
Cardiac toxicity Electrocardiography, 24 h monitoring and
echocardiography did not reveal any evidence of cardiac
toxicity. Q-T intervals were analysed on ECG recordings and
did not show any significant prolongation with the quinidine
doses used. At the end of a full course of epirubicin, repeat
echocardiography showed no evidence of significant impair-
ment of LV function (four patients).
Quinidine levels
The median plasma concentrations of quinidine in patients
are shown in Table III. In the 250 mg b.d. group the median
level was 5.6ftmol I'. This is in the range active in vitro
(Stallard & Kaye, 1989). The median level in patients taking
500 mg b.d. of quinidine was 7.4jsmol 1'.
Discussion
Drug resistance remains a major problem in the management
of advanced breast cancer by chemotherapy. The response
rate to the most active single agent, adriamycin is limited to
40-50%, and it is possible that one mechanism underlying
TableI Summaryoftheoutcomeof21 patientswhoreceivedquinidine
250 mg b.d. with epirubicin (includes onepatient treated with quinidine
500 mg b.d. for one cycle)
No. patients Outcome
6 completed planned 8 cycles
7 off no response/PD
2 off quinidine toxicity
I cinchonism, I dizziness
I offmyelosuppression, 6 cycles
I off skin reaction, 6 cycles
I off nausea and vomiting, 7 cycles
I off oral toxicity after I cycle
I off declined last cycle with PR
I off because crushing durules
TableII Summaryofhaematologicaltoxicityfortreatmentcycleswith
and without quinidine
Cycle 1, cycles 2-4, Cycles 4-8,
without with with
quinidine quinidine quinidine
Median
WBC nadir 2.3 1.5 1.6
(x 1091l-)
Range 1.1-4.5 1.0-5.9 0.7-5.2
Median
platelet 175 158 156
nadir(x 1091-l)
Range 85-565 37-565 54-307
Table III Summary ofpatient plasma quinidine levels achieved with
different quinidine doses
Median
Number of Number of quinidine
patients Quinidine dose cycles level (p.mol1-')
3 1 gb.d. 1 12
8 500 mg b.d. 28 7.4
(2.9-13.2)
20 250 mg b.d. 77 5.6
(2.1-22.1)
this is the so-called multidrug resistance phenomenon. This
study aimed to investigate if it were feasible to combine the
response modulator, quinidine, active in the laboratory, with
epirubicin, an anthracycline recently extensively studied in
this centre. We also examined whether levels of quinidine
known to be active in vitro could be achieved in patients, and
whether the two drugs could be combined without enhance-
ment of epirubicin toxicity.
The dose of quinidine of 1 g b.d. was selected as this dose
has been found to be well tolerated by patients receiving the
drug for reasons of cardiac dysrhythmia. Our three patients
who received quinidine at this dose developed side-effects
and, even at a dose of 500 mg b.d., three of eight patients
developed problems, although one of these, who complained
of nausea, subsequently completed the full eight cycles with-
out problem when the dose of quinidine was reduced to
250 mg b.d.
Twenty patients were then entered at a quinidine dose of
250 mg b.d. Two of these were discontinued from their
quinidine because of symptoms attributed to the drug. Inter-
estingly, one developed symptoms of cinchonism with a
plasma level of drug of only 3.4j.mol; this effect generally
occurs only with high drug levels. Three further patients did
not complete all planned therapy because of toxicity
associated with epirubicin. One of these stopped after one
course because of mucositis, a recognised problem with
epirubicin alone, and in this case occurring before any
quinidine therapy. The problems in the other two patients
were of nausea and vomiting and myelosuppression. These
again are toxicities associated with epirubicin and were com-
parable with our experience using this drug alone at a dose
of 100 mg m-2 (Habeshaw, personal communication).
Myelosuppression was not a significant problem in this study
and nadir data did not show evidence of enhancement of
bone marrow toxicity by the response modulator. Only one
patient in the 250 mg group required dose reduction because
of myelosuppression.
In view of the effects of quinidine on heart rhythm and the
known dose-dependent cardiotoxicity of anthracyclines,
careful attention was paid to heart rhythm and function. No
evidence of cardiac toxicity was found in any patient in the
study. The median quinidine level in patients treated for 4
days at a dose of 250 mg in slow release form was
5.6 gAmol 1-'. This is clearly in the range active in the
laboratory (Stallard & Kaye, 1989). Higher doses of
quinidine did, as might be expected, produce higher, but not
necessarily more useful, levels.QUINIDINE AND EPIRUBICIN 135
In summary, treatment of patients with advanced breast
cancer with a combination of quinidine and epirubicin
appears feasible. The combination does not appear to pro-
duce more toxicity than epirubicin alone, and at a dose of
250 mg b.d. quinidine levels equivalent to those active in vitro
are achievable in patients.
The question remains as to whether an improvement in
response rate and survival can be achieved in the clinic, by
the use of quinidine to overcome anthracycline resistance. In
view of our data on MDR expression in samples from
previously untreated patients, we have chosen to address this
question in a randomised, prospective, placebo-controlled
trial, using epirubicin as initial chemotherapy for patients
with advanced disease.
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